SPORE IN PROSTATE CANCER

每年有超过38,000名美国人死于前列腺癌， 死于手枪的人数 骨转移是毁灭性的， 当疾病变成激素时没有有效的治疗方法 难治的 这种前列腺孢子更新是一个多学科的 减少发病率、发病率和 前列腺癌的死亡率如下。预防：DNA 人谷胱甘肽-S-转移酶基因的甲基化改变 在这项资助中发现的是最常见的基因组改变， 据报道，在前列腺癌，扭转这是一个目标， 建议进行饮食和化学预防研究。 遗传学：在 前列腺癌家系，遗传连锁研究 将确定遗传性前列腺癌的候选基因 基因 癌症基因型和肿瘤抑制因子的表征 并进行基因测序。 早期发现和 诊断：血清前列腺特异性抗体的变化速度 抗原和血清性类固醇水平将与癌症相关 在巴尔的摩老龄化纵向研究中， 最大和最长的纵向老化研究。非洲裔 增加了前列腺癌的发病率和死亡率， 将在雄激素的分子流行病学中进行研究， 受体基因结构 改善诊断和预后， 使用新的SPORE发现的生物标志物的新算法进行研究， 高分辨率定量病理学技术; Kai-1转移抑制基因的表达及其计算研究 人前列腺癌细胞核的染色质结构。 发病率 减少：加速改善前列腺癌的进展 患者的生活质量，研究的重点是生理 前列腺癌骨转移 治疗方法：此孢子开发 第一个晚期前列腺癌的人类基因疗法， 现在NIH RAC批准进行临床试验。 新疗法使用新的 用于基因治疗的载体，拓扑异构酶靶向药物， 免疫疗法和放射疗法正在设计中。 试点项目 针对致癌物的人群研究， 流行病学因素;和新的药物模式，以提高细胞 死亡 建立了大型核心组织库， 将人类前列腺研究转化为临床医学。 新 正在培养和建立年轻的调查人员 其他领域的研究人员也被吸引到前列腺的研究上 癌 这是一项高度互动的临床和基础研究 团队致力于将新发现转化为控制 前列腺癌

Each year prostate cancer kills over 38,000 Americans, almost twice the number killed by handguns. Bone metastasis is devastating, and no effective therapy exists when the disease becomes hormone refractory. This Prostate SPORE renewal is a multidisciplinary approach to address methods to reduce the incidence, morbidity, and mortality of prostate cancer as follows. Prevention: DNA methylation changes in the human glutathione-S-transferase gene discovered in this grant are the most common genomic alterations reported in prostate cancer, and reversing this is a target of the proposed dietary and chemoprevention studies. Genetics: In families with pedigrees of prostate cancer, genetic linkage studies will identify candidate genes as the Hereditary Prostate Cancer gene. Characterization of cancer genotypes and tumor suppressor gene sequencing will also be conducted. Early Detection and Diagnosis: The velocity of change in serum prostatic specific antigen and serum sex-steroid levels will be correlated with cancer risk in the Baltimore Longitudinal Study of Aging, the world's largest and longest longitudinal aging study. African-Americans have increased prostate cancer incidence and mortality, and this will be studied in the molecular epidemiology of the androgen receptor gene structure. Improved diagnosis and prognosis are studied by new algorithms using new SPORE discovered biomarkers and high resolution quantitative pathology techniques; study of the Kai-1 metastasis suppressor gene; and computational study of chromatin structure in human prostate cancer nuclei. Morbidity Reduction: To accelerate progress in improved prostate cancer patient quality of life, research is focused on the physiology of prostrate cancer bone metastases. Treatment: This SPORE developed the first human gene therapy for advanced prostate cancer which is now NIH RAC approved for clinical trials. New therapies using new vectors for gene therapy, topoisomerase-targeted drugs, immunotherapy, and radiotherapy are being designed. Pilot Projects are targeted on population studies of carcinogens and epidemiological factors; and new drug modalities to enhance cell death. A large core tissue bank has been established to accelerate translation of human prostate research to clinical medicine. New young investigators are being developed and established investigators in other fields are being attracted to study prostate cancer. This is a highly interactive clinical and basic research team dedicated to translate new discoveries to the control of prostrate cancer.